You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.
In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.
In PLOS this week: gene expression in muscle stem cells, blood metabolomic study of diabetic retinopathy complications, and more.
The aggressive subtype, uncovered by a team of researchers in Germany, may also be susceptible to targeted therapy that blocks interferon signaling.
In PNAS this week: possible cancer targets due to homologous recombination defects, approach for detecting digenic disease inheritance, and more.
Transcription factor reprogramming during prostate cancer metastases appears to involve epigenetic changes that resemble those at play during prostate development, new research finds.
While a subset of metastatic castration-resistant tumors was marked by enhanced methylation, the analysis also pointed to recurrently hypomethylated regions.
Dogs age more rapidly in their early years but then age more slowly later on, a DNA methylome analysis found, changing how dogs' ages are translated to human ages.
The firm touts a new hybridization probe design, which it says will enable small, focused panels that reduce sequencing costs and assay time.
The Oxford, UK-based firm announced the closure of a seed financing round this week as well as plans to develop a methylation-based blood test for early-stage cancer detection.
SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.
The New York Times reports that a new viral variant of concern has been identified in New York City.
In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.
CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.